hoag.jpg

HOSPITAL WITH LOWEST READMISSION RATE SHARES MORE DATA

Posted On April 25, 2017 By OrthoSpineNews In Recon, Top Stories /  

Elizabeth Hofheinz, M.P.H., M.Ed. • Thu, April 20th, 2017

Orange County California’s Hoag Orthopedic Institute (HOI), just released its 2017 Outcomes Report.  In it, readers can find information regarding HOI’s previous year’s surgical volumes, care quality metrics, infection and readmission rates, and patient satisfaction scores.

HOI has performed the most joint replacements in California for five consecutive years. It has also had the lowest readmission rate in the nation for hip and knee replacements from 2012 through 2015.

In addition to the data on infection rates and volume, the report also highlights quality improvement initiatives, distinctions and innovations, details on HOI’s education and research program, compelling patient testimonials, and much more.

“Our quest to provide greater value and optimize outcomes in musculoskeletal care unfolds in this issue of our annual outcomes report,” said Sopida Andronaco, R.N., director of Performance Improvement and Clinical Outcomes for HOI. “The entire HOI staff works tirelessly to continually reach this exemplary level of excellence and we are proud to showcase their dedication and commitment to delivering quality care to our patients.”

 

READ THE REST HERE

Read More
amedica_nass_booth.jpg

Amedica Announces Regulatory Clearance to Market and Sell Valeo® Silicon Nitride Spinal Implants in Australia

Posted On April 25, 2017 By OrthoSpineNews In Regulatory, Spine, Top Stories /  

SALT LAKE CITY, UT–(Marketwired – Apr 24, 2017) – Amedica Corporation (NASDAQ: AMDA), an innovative medical device company that develops and commercializes silicon nitride, is pleased to announce it has been granted marketing clearance for its Valeo interbody fusion devices in Australia.

The Valeo product line is made entirely of Amedica’s proprietary medical grade silicon nitride ceramic — an ideal material for fusion because of its nanostructured surface, osteoconductivity, osteoinductivity, anti-microbial properties, and ease of radiographic imaging.

“The Australian clearance is a tremendous opportunity for Amedica. Interestingly, during 1986-1988, Australian surgeons and engineers were the first to synthesize reaction-bonded silicon nitride, and implant the material in lumbar spine fusion patients. Favorable outcomes in terms of pain relief and successful fusion were reported at the 15-year follow-up time interval. Thus, the pioneering clinical use of silicon nitride in spine fusion originated in Australia, and we are excited to see the material return to its place of birth,” said Dr. Sonny Bal, CEO. “The successful outcomes from Australia are now validated by 45 scientific papers published by Amedica in top-tier peer journals, and clinical data that will be published throughout this year. We look forward to working with Australian surgeons, and providing them with improved options for spinal fusion surgery.”

About Amedica Corporation
Amedica is the only manufacturer of medical grade silicon nitride — an innovative biomaterial technology ideal for use in spinal fusion and across a variety of medical applications. The Company’s products are manufactured in its ISO 13485 certified manufacturing facility located in Salt Lake City, Utah. Amedica’s FDA-cleared and CE-marked spine products are currently marketed in the U.S. and select markets in Europe and South America through its distributor network.

For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, but are not limited to, the Company’s opportunities for global expansion, and the Company’s future commercialization plans. Such statements are subject to risks and uncertainties such as whether the FDA approves the Company’s submission, the timing of such approval and the Company’s success in commercializing its products. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 23, 2016, and in Amedica’s other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.

CONTACT INFORMATION

Read More
SteriSpinePS.jpg

Pascale Davis, an internationally renowned expert on the spine market, joins Safe Orthopaedics as Global Head of Marketing

Posted On April 24, 2017 By OrthoSpineNews In Spine, Top Stories /  

April 24, 2017

ERAGNY-SUR-OISE, France–(BUSINESS WIRE)–Regulatory News:

SAFE ORTHOPAEDICS (Paris:SAFOR) (FR0012452746 – SAFOR), a company offering an innovative range of sterile implants combined with their single-use instruments for spinal surgery, is today announcing the appointment of Pascale Davis, an internationally renowned expert on the spine market, as Global Head of Marketing.

Pascale is a seasoned veteran with over 18 years’ experience in marketing and scientific affairs. She worked for industry leaders including Zimmer Biomet, Synthes and SpineArt, where she acquired both marketing and scientific knowledge in Europe and in the United States.

Before joining Safe Orthopaedics, Pascale was Marketing Director for Europe, Middle East and Africa (EMEA) at Zimmer Biomet Spine, since 2012 where initially her role was EMEA Scientific Affairs Director. Previously, she held various positions of responsibility at Synthes Spine and SpineArt in Switzerland and then in the United States. Concurrently, Pascale was also Director of Education and Marketing for the International Society for Advancement of Spinal Surgery (ISASS) from 2001 until 2006.

“It gives us great pleasure to welcome Pascale to Safe Orthopaedics. Her arrival illustrates the Company’s ability to attract well-known international talents and the growing interest in its technology, as was recently demonstrated by AP-HP’s decision to list our products,” commented Pierre Dumouchel, Co-Founder and Chief Executive Officer of Safe Orthopaedics. “Pascale’s arrival will provide a significant boost to our marketing capabilities and training programs that we provide to surgeons to foster the take-up of our products and to give them more information about the benefits of Safe Orthopaedics’ sterile single-use products for both minimally-invasive and trauma surgery.”

Pascale Davis, Safe Orthopaedics’ Head of Global Marketing, added: “I’m delighted to be joining Safe Orthopaedics. Their innovative technology is highly acclaimed and respected and gaining more and more traction in France and internationally. I will be applying my market knowledge together with the experience I gained in the scientific community to accelerate adoption of our products by surgeons and centers of excellence for spinal surgery — in France, Germany and also in other European and emerging markets.”

Next report: Full-year 2016 results on Friday, April 28, 2017

About Safe Orthopaedics

Founded in 2010, Safe Orthopaedics is a French medical technology company that aims to make spinal surgeries safer by using sterile implants and associated single-use instruments. Through this approach, these products eliminate all risk of contamination, reduce infection risks and facilitate a minimally-invasive approach for trauma and degenerative pathologies—benefiting patients. Protected by 17 patent families, the SteriSpineTM kits are CE-marked and FDA approved. The company is based at Eragny-sur-Oise (Val d’Oise department), and has 30 employees.

For more information, visit: www.SafeOrtho.com

Contacts

Safe Orthopaedics
Thierry Lambert, +33 (0)1 34 21 50 00
CFO
investors@safeorthopaedics.com
or
NewCap
Julien Perez / Valentine Brouchot
Investor Relations
Nicolas Merigeau
Media Relations
+33 (0)1 44 71 94 94
SafeOrtho@newcap.eu

Read More
duke-university-3d-printed-cartilage-mimicking-hydrogels-could-repair-damaged-knees-1.jpg

3-D Printable Implants May Ease Damaged Knees

Posted On April 21, 2017 By OrthoSpineNews In Biologics, Top Stories /  

PUBLISHED IN  – By KARA MANKE

A cartilage-mimicking material created by researchers at Duke University may one day allow surgeons to 3-D print replacement knee parts that are custom-shaped to each patient’s anatomy.

Human knees come with a pair of built-in shock absorbers called the menisci. These ear-shaped hunks of cartilage, nestled between the thigh and shin bones, cushion every step we take. But a lifetime of wear-and-tear — or a single wrong step during a game of soccer or tennis — can permanently damage these key supports, leading to pain and an increased risk of developing arthritis.

The hydrogel-based material the researchers developed is the first to match human cartilage in strength and elasticity while also remaining 3-D-printable and stable inside the body. To demonstrate how it might work, the researchers used a $300 3-D printer to create custom menisci for a plastic model of a knee.

“We’ve made it very easy now for anyone to print something that is pretty close in its mechanical properties to cartilage, in a relatively simple and inexpensive process,” said Benjamin Wiley, an associate professor of chemistry at Duke and author on the paper, which appears online in ACS Biomaterials Science and Engineering.

After we reach adulthood, the meniscus has limited ability to heal on its own. Surgeons can attempt to repair a torn or damaged meniscus, but often it must be partially or completely removed. Available implants either do not match the strength and elasticity of the original cartilage, or are not biocompatible, meaning they do not support the growth of cells to encourage healing around the site.

Recently, materials called hydrogels have been gaining traction as a replacement for lost cartilage. Hydrogels are biocompatible and share a very similar molecular structure to cartilage: if you zoom in on either, you’ll find a web of long string-like molecules with water molecules wedged into the gaps.

READ THE REST HERE

Read More
drop-back-series-suture-strand.jpg

Ziptek LLC Receives FDA Approval For ZipE®, the Innovative Knotless Tissue Repair Device

Posted On April 21, 2017 By OrthoSpineNews In Regulatory, Top Stories /  

By on April 20, 2017

Ziptek LLC, founded by Sarasota-based orthopedic surgeon Dr. William Bennett M.D., is proud to announce its newly obtained FDA-approval for the ZipE® knotless tissue repair and attachment device. ZipE® is an absorbable button that moves down a suture, locking itself from moving backward with each forward movement. It can be used in minimally-invasive techniques and open surgeries to accomplish tissue-to-tissue and tissue-to-bone repair. Most importantly, since it functions similar to a zip tie, ZipE® prevents the need to tie knots in small spaces and creates a superior contact of the repaired tissue compared to any other device on the market.

Ziptek LLC exhibited at the March 2017 AAOS Meeting in San Diego and garnered significant national and international interest by surgeons and distributors alike for the newly FDA-approved ZipE®. Given that the U.S soft tissue repair market generates $2 to $3 billion per year, with at least 500,000 rotator cuff and 1,000,000 ankle ligament cases annually, the ZipE® can play a major role in transforming the surgical outcomes of countless patients. It offers the unprecedented ability to disperse pressure across a larger surface area and help prevent the suture from tearing out through the tissue. This makes ZipE® incredibly valuable for better and improved tissue healing with a far lower rate of non-healing and re-tears.

 

 

READ THE REST HERE

Read More
7d-surgical-7x4.jpg

7D Surgical Enters Into Key Distribution Agreements in the United States for Its Breakthrough Image Guidance System for Spine Surgery

Posted On April 21, 2017 By OrthoSpineNews In Spine, Top Stories /  

TORONTO, April 20, 2017 /PRNewswire/ — 7D Surgical, developer of ground breaking surgical navigation technologies, announced today that it has entered into exclusive sales representative agreements with two premier American medical device distributors covering key strategic geographies in the United States.  Surgical One Inc. will represent 7D Surgical in several states from the Midwest to the Gulf Coast, while DB Surgical will cover the southeast U.S., including the important medical device markets in Florida.

“Proven distribution partners, such as Surgical One and DB Surgical, will complement our direct sales force in the commercialization of the MvIGS technology for the execution of our rapid growth strategy,” said Beau Standish, Chief Executive Officer of 7D Surgical.  “Both companies have the infrastructure, footprint and existing relationships that are required to effectively promote the benefits of 7D Surgical’s fast, cost effective and radiation-free image guided spine surgery to a large and underserved market.”

The 7D Surgical System is the first and only Machine-Vision Image Guided Surgery (MvIGS) platform. For the first-time spine surgery patients can be quickly, easily and automatically registered using only visible light and 7D Surgical’s Flash RegistrationTM technology. Unlike time-consuming conventional image guided surgery (IGS) systems that depend on intraoperative radiation, this new MvIGS platform can achieve an incredibly fast surgical workflow for spine procedures. 7D Surgical anticipates adding additional qualified distribution partners in coming months.

“When Surgical One learned about the new MvIGS system, we recognized immediately that the 7D Surgical technology had erased the traditional barriers to spinal image guidance adoption and the low utilization of existing alternatives,” said Al Ludvigsen, President of Surgical One Inc. “We are thrilled to exclusively represent this fast, radiation-free solution for spinal image guidance to the clinicians and patients we support.”

“While spinal image guidance had been shown in studies to reduce surgical complications, we have yet to see widespread adoption of existing technologies among spinal surgeons,” said Debbie Burg, President of DB Surgical.  “We see the introduction of the 7D Surgical System MvIGS technology as a game-changer with the potential to finally expand the use of IGS in spine surgery.”

About 7D Surgical

7D Surgical is a privately owned Toronto-based company that develops advanced optical technologies and machine vision-based registration algorithms to improve surgical workflow and patient care. 7D Surgical’s flagship FDA 510(k)-cleared and Health Canada-approved MvIGS system delivers profound improvement to surgical workflows in spine surgery, providing the promise of similar future advancements in other surgical specialties.  www.7Dsurgical.com

Contact:
Beau Standish, CEO
7D Surgical
+1 647 484-0078
www.7Dsurgical.com
155698@email4pr.com

About Surgical One, Inc.

SurgicalOne, Inc. is the premier surgical specialty distribution company in the Midwest to Midsouth. Our 30 direct employees cover 10 total states, with sales representatives and service repair technicians in each major market. We represent the top tier, finest microsurgical, neurosurgical and spinal product manufacturers in the world. Since our founding in 2000, we have maintained a relentless, singular focus on patients, surgical clinicians and medical facility administrators. Our ultimate goal is improved patient outcomes, combined with the highest level of clinician satisfaction. www.surgicalone.com

About DB Surgical

DB Surgical is dedicated to bringing transformational surgical technologies to hospitals and surgery centers. The company focuses on introducing tools that enable surgeons to advance patient outcomes beyond those available today. Since 1997, DB Surgical has worked with industry-leading surgeons to understand and meet the evolving needs of healthcare providers. The company is based in Coral Springs, FL and has 18 professionals located throughout Florida, Georgia, and Alabama focusing on the Neuro, Spine, ENT, Cardiovascular, Ophthalmic, and Plastic Reconstructive surgical disciplines. In addition to providing cutting-edge technologies, DB Surgical also offers a complete line of specialty surgical products designed to create value within the healthcare supply chain. www.DBSurgical.com.

Contact:
Phone: 954-340-2727
Fax: 954-340-1221
Email: sales@dbsurgical.com

Forward-looking Statements

This press release contains forward-looking statements regarding, among other things, statements pertaining to expectations, goals, plans, objectives, and future events. 7D Surgical intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934, and the Private Securities Reform Act of 1995. In some cases, forward-looking statements can be identified by the following words: “may,” “can,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “promise,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions, and other factors that may cause actual results to differ materially from those indicated by forward-looking statements, many of which are beyond 7D Surgical’s ability to control or predict. Given these uncertainties, undue reliance should not be placed on these forward-looking statements. 7D Surgical does not undertake any obligation to release publicly any updates or revisions to these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

“Flash Registration™,” as well as the “7D” logo, whether standing alone or in connection with the words “7D Surgical” are protected trademarks of 7D Surgical.

SOURCE 7D Surgical

Related Links

http://www.7Dsurgical.com

Read More
xm_p5135169.jpg.pagespeed.ic_.rXaTias2lg.jpg

Northwell Announces Affiliation Agreement With Acclaimed Orthopedic Institute

Posted On April 20, 2017 By OrthoSpineNews In Extremities, Sports Medicine, Top Stories /  

NEW HYDE PARK, N.Y., April 20, 2017 /PRNewswire-USNewswire/ — Northwell Health has signed a strategic affiliation agreement with the Rothman Institute, one of the nation’s largest, most-prestigious orthopedic practices.

Headquartered in Philadelphia, Pennsylvania, Rothman Institute is known internationally as a preeminent orthopedic and musculoskeletal practice, with more than 25 locations throughout Pennsylvania and New Jersey, including two orthopedic urgent care clinics.  Rothman Institute is recognized for their innovative treatment methods, research, education and technology.

The Northwell Health Orthopaedic Institute will be working with Rothman Institute to develop centers of excellence for orthopedic care in the New York Metropolitan area, including Manhattan.

“We’re excited about the affiliation with the Rothman Institute,” said Nicholas Sgaglione, MD, chair of orthopedics at Northwell Health. “The affiliation will bring together two nimble, forward-thinking organizations that emphasize high-quality care. We also look forward to working with the Rothman Institute to co-brand various marketing initiatives, the ongoing recruitment of top-level physicians, joint research, and tracking and measuring patient outcomes.”

“We look forward to joining the Northwell Health family,” said Alexander R. Vaccaro, MD, PhD, MBA, president of Rothman Institute, Richard H. Rothman Professor and chairman of the Department of Orthopaedics, and professor of neurosurgery at Thomas Jefferson University and Hospitals. “This agreement expands Rothman Institute’s footprint into New York City and the surrounding suburbs. We are looking forward to bringing our excellent musculoskeletal care to Northwell Health’s communities and patients now and for years to come.”

About Northwell Health
Northwell Health is New York State’s largest health care provider and private employer, with 21 hospitals and over 550 outpatient practices. We care for more than two million people annually in the metro New York area and beyond, thanks to philanthropic support from our communities. Our 61,000 employees – 15,000+ nurses and nearly 3,400 physicians, including nearly 2,700 members of Northwell Health Physician Partners – are working to change health care for the better. We’re making breakthroughs in medicine at the Feinstein Institute. We’re training the next generation of medical professionals at the visionary Hofstra Northwell School of Medicine and the School of Graduate Nursing and Physician Assistant Studies. And we offer health insurance through CareConnect. For information on our more than 100 medical specialties, visit Northwell.edu.

About Rothman Institute
Rothman Institute is a private orthopaedic practice dedicated to providing communities with high-quality, compassionate, and affordable musculoskeletal care that is grounded in evidence-based medicine, the results of which will exceed expectations. Rothman Institute orthopaedists treat patients at over 25 locations in the Philadelphia-region, including orthopaedic urgent care clinics in Marlton, NJ and Limerick, PA.

With experts in orthopaedic sub-specialties including spine, hip and knee, foot and ankle, shoulder and elbow, hand and wrist, sports medicine, physical medicine and  rehabilitation, orthopaedic oncology and trauma, Rothman Institute is internationally recognized for excellence in clinical treatment  methods, research, education and technology. Consistently recognized as national and regional “Top Docs,” Rothman Institute is proud to be the first practice serving as official team physicians for all four of the major professional sports teams in one city, the Philadelphia Eagles, Phillies, Flyers and 76ers, as well as over 40 college and high school teams. For more information about Rothman Institute please call 1-800-321-9999 or visit www.RothmanInstitute.com.

SOURCE Northwell Health

Related Links

https://www.northwell.edu

Read More
iFactor_iFactor_WEB.jpg

Oxford Finance Provides $20 Million Senior Debt Facility to Cerapedics Inc.

Posted On April 19, 2017 By OrthoSpineNews In Financial, Top Stories /  

ALEXANDRIA, Va. and WESTMINSTER, Colo., April 19, 2017 /PRNewswire/ — Oxford Finance LLC (“Oxford”), an industry-leading specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced the closing of a $20 million senior secured term loan with Cerapedics Inc. (“Cerapedics”) a privately-held orthobiologics company engaged in the development and commercialization of bone graft substitute products for the treatment of orthopedic injuries.

Cerapedics’ lead product, i-FACTOR Peptide Enhanced Bone Graft, is the only biologic bone graft that uses a unique small peptide attachment factor (P-15) bound to anorganic bone mineral (ABM). The i-FACTOR is the first and only FDA-approved product for Anterior Cervical Discectomy and Fusion (ACDF) and is the first device to demonstrate superiority versus autograft.

Loan proceeds are being used to support the ongoing commercialization of i-FACTOR’s use in cervical spine procedures and help fund a FDA study on its application in Transforaminal Lumbar Interbody Fusion (TLIF.)

“We are encouraged by the strength of i-FACTOR’s clinical safety and efficacy data,” said Christopher A. Herr, senior managing director at Oxford Finance. “Oxford is pleased to provide capital to help Cerapedics continue to enhance the science of bone repair.”

“We are pleased to be working with a strong partner in Oxford Finance in executing on our key growth initiatives,” said Glen Kashuba, chief executive officer of Cerapedics.

About Oxford Finance LLC

Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. Oxford has originated over $4 billion in loans, with credit facilities ranging from $5 million to $100 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in San Diego, California; Palo Alto, California; Salt Lake City, Utah and the greater Boston area. For more information, visit oxfordfinance.com.

About Cerapedics Inc.

Cerapedics is an orthobiologics company focused on developing and commercializing its proprietary synthetic small peptide (P-15) technology platform. i-FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. This novel mechanism of action is designed to support safer and more predictable bone formation compared to commercially available bone growth factors. More information can be found at cerapedics.com.

Media Contacts:

Amanda Stern 

Troy Wilford

Oxford Finance LLC 

Cerapedics Inc.

Tel: (888)471-0174 

Tel: (484)247-8054

astern@oxfordfinance.com 

twilford@cerapedics.com

 

SOURCE Oxford Finance Corporation

Related Links

http://www.oxfordfinance.com

Read More
NuVasive-Headquarters.jpg

NuVasive Launches New Spinal Trauma Portfolio

Posted On April 19, 2017 By OrthoSpineNews In Spine, Top Stories /  

SAN DIEGO, April 19, 2017 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the launch of the new RELINE® Trauma portfolio, which will serve as the Company’s foundation to address the estimated $100 million U.S. spine trauma fixation market, currently growing 5.6 percent annually.

Spine trauma cases are performed approximately 90 percent open and only 10 percent minimally-invasive. RELINE Trauma is the first trauma system designed to provide surgeons the flexibility to customize their approach intra-operatively, including traditional open, MAS® (Maximum Access Surgery) or hybrid procedures, depending on the pathology and patient needs. Developed by the leader in minimally disruptive spine technology, the Company’s new trauma system supports surgeons in the increasing transition from open to MAS spine procedures.

The system offers surgeons the ability to customize implant types and supports a multitude of techniques, depending on surgeon preference. Also, RELINE Trauma enhances the surgeon’s ability to dial-in fracture correction through a dual rack system achieving independent lordosis restoration and parallel compression/distraction for ligamentotaxis. This enables procedures to be completed by one surgeon rather than two, helping reduce the total cost of the procedure.

“The versatility of the new RELINE Trauma system allows me to address trauma surgery circumferentially,” said Juan Uribe, M.D., Associate Professor, Department of Neurosurgery, University of South Florida College of Medicine, Tampa, Florida. “NuVasive has removed the need for a second surgeon and eliminated hours in comparison to the alternative technique. RELINE Trauma is a game-changer in spine.”

In addition, the RELINE Trauma Fracture Frame instrumentation allows for controlled fracture correction throughout the procedure, with or without a rod present in the construct. The systems also allows surgeons the ability to place various rod diameters and/or materials before or after fracture correction, greatly improving the ability to reduce fractures more easily and reproducibly.

“The launch of RELINE Trauma is a key milestone in our continued commitment to industry-leading innovation that delivers untapped clinical and economic value for our surgeon partners,” said Jason Hannon, president and chief operating officer of NuVasive. “RELINE Trauma will help define the standard of trauma care for spine, with its ability to dramatically reduce time and provide complete versatility intra-operatively. The system will be the foundation of our trauma portfolio as we invest further in this key market.”

RELINE Trauma is further integrated with proprietary NuVasive Computer Assisted Technologies such as NVM5®, NuvaLine™, NuvaMap® and NuvaMap® O.R., all within the Integrated Global Alignment® (iGA) platform. iGA allows surgeons to calculate, correct and confirm spinal alignment through preoperative planning, intraoperative assessment, and postoperative confirmation for their trauma cases. Additionally, constructs are further enhanced with the integration of the Bendini® system which expedites manual rod manipulation via computer-assisted bend instructions.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes. NuVasive’s highly differentiated, procedurally-integrated solutions include access instruments, implantable hardware and software systems for surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries around the world. For more information, please visit www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

 

SOURCE NuVasive, Inc.

Related Links

http://www.nuvasive.com

Read More
46210783_l-1-e1453303297665.jpg

Inspired Spine Achieves Milestone of 500 Minimally Invasive OLLIF Procedures

Posted On April 13, 2017 By OrthoSpineNews In Spine, Top Stories /  

MINNEAPOLIS, MINNESOTA (PRWEB) APRIL 12, 2017

Inspired Spine, a Minnesota-based spine surgery innovation company, has reached the milestone of completing 500 Oblique Lateral Lumbar Interbody Fusion (OLLIF) procedures. This truly minimally invasive surgical technique is revolutionizing the performance of lumbar interbody fusions by delivering superior outcomes including substantially less patient recovery time and minimal blood loss, while requiring a procedure duration as short as 30 minutes.

The OLLIF procedure is a minimally invasive lumbar fusion technique that employs an incision of 15 millimeters, produces 80% less blood loss than a traditional fusion, and requires no muscle detachment to access the disc space. After a surgeon learns this technique, the procedure requires less than one third of the time required to perform a traditional fusion procedure, decreasing the patient’s anesthesia risk and increasing OR throughput efficiency.

Remarkably, many patients are ambulatory within two hours after surgery and are often discharged the same day. No infections have occurred during the first 500 procedures.

Numerous studies have been and are currently being performed during the journey to the 500th procedure. One study that has been published in the peer reviewed journal Cureus and presented at several national meetings is “Economic Performance of Oblique Lateral Lumbar Interbody Fusion (OLLIF) with a Focus on Hospital Throughput Efficiency.” This study demonstrated that due to its substantially reduced surgical time and shorter required hospital stay duration, the OLLIF procedure has saved hospitals an average of $9500 per case while improving patient outcomes.

Inspired Spine has also developed two derivative lumbar fusion techniques from the OLLIF approach: 1) MIS-DLIF and 2) MIS-DTIF. MIS-DLIF enables minimally invasive lumbar fusions to be successfully performed at L5-S1, overcoming the obstacles presented by the ala of the sacrum and the iliac crest. MIS-DTIF enables minimally invasive fusion of the thoracic levels of the spine, eliminating the risks associated with traditional thoracic approaches.

Additionally, OLLIF, MIS-DLIF and MIS-DTIF have been employed to successfully treat adult degenerative scoliosis for several of the first 500 patients.

Said Chief Medical Officer Hamid Abbasi MD, “Inspired Spine’s mission is to improve patient outcomes by substantially upgrading the surgical standard of care to that which is truly minimally invasive to deliver maximum improvements to each patient. Therefore, our team developed the capability to effectively employ the OLLIF and its derivative techniques throughout the lumbar and thoracic spine. Our data from the 500 procedures demonstrates and documents exceptional outcomes with minimal complications!”

Inspired Spine offers regular training sessions for surgeons nationwide including cadaver labs and on-site proctoring. Additionally, patients can locate an Inspired Spine Certified physician for treatment by visiting InspiredSpine.com.

About Inspired Spine

Inspired Spine, a Minnesota-based advanced minimally invasive spinal surgery technology developer, has introduced and performed over 500 procedures using revolutionary new technologies and procedures in advanced minimally invasive systems. These new procedures are transforming how spinal surgeries are approached and can replace more traditional “open” spinal fusion surgeries.

Inspired Spine is focused on the development of advanced minimally invasive surgical techniques, procedures and other health care technology to minimize or eliminate the physical and economic risks and discomfort that are created by the daily struggles of enduring back pain and its physical limitations. Learn more at http://inspiredspine.com/.

Contact for Inspired Spine:
David Greene, 602-677-8981
dgreene(at)theusleadnetwork.com

Read More